GB2192183B - A crystalline oral cephalosporin hydrate and its compositions - Google Patents

A crystalline oral cephalosporin hydrate and its compositions

Info

Publication number
GB2192183B
GB2192183B GB8715064A GB8715064A GB2192183B GB 2192183 B GB2192183 B GB 2192183B GB 8715064 A GB8715064 A GB 8715064A GB 8715064 A GB8715064 A GB 8715064A GB 2192183 B GB2192183 B GB 2192183B
Authority
GB
United Kingdom
Prior art keywords
hydrate
crystalline
compositions
oral cephalosporin
cephalosporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB8715064A
Other languages
English (en)
Other versions
GB8715064D0 (en
GB2192183A (en
Inventor
Yoshio Hamashima
Kyoji Minami
Kyozo Kawata
Teruo Sakamoto
Toyohiko Takeda
Yusuke Suzuki
Masonori Tujikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP61156954A external-priority patent/JP2544113B2/ja
Priority claimed from JP21626086A external-priority patent/JPH0717651B2/ja
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of GB8715064D0 publication Critical patent/GB8715064D0/en
Publication of GB2192183A publication Critical patent/GB2192183A/en
Application granted granted Critical
Publication of GB2192183B publication Critical patent/GB2192183B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
GB8715064A 1986-07-02 1987-06-26 A crystalline oral cephalosporin hydrate and its compositions Expired - Lifetime GB2192183B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61156954A JP2544113B2 (ja) 1986-07-02 1986-07-02 安定なカプセル製剤
JP21626086A JPH0717651B2 (ja) 1986-09-12 1986-09-12 経口投与用セフアロスポリン水和物結晶

Publications (3)

Publication Number Publication Date
GB8715064D0 GB8715064D0 (en) 1987-08-05
GB2192183A GB2192183A (en) 1988-01-06
GB2192183B true GB2192183B (en) 1990-05-16

Family

ID=26484565

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8715064A Expired - Lifetime GB2192183B (en) 1986-07-02 1987-06-26 A crystalline oral cephalosporin hydrate and its compositions

Country Status (27)

Country Link
US (2) US4812561A (OSRAM)
KR (1) KR950005302B1 (OSRAM)
CN (1) CN1015106B (OSRAM)
AR (1) AR243893A1 (OSRAM)
AT (1) AT392472B (OSRAM)
AU (1) AU594167B2 (OSRAM)
BE (1) BE1001691A4 (OSRAM)
CA (1) CA1283405C (OSRAM)
CH (1) CH672788A5 (OSRAM)
DE (1) DE3721913A1 (OSRAM)
DK (1) DK161080C (OSRAM)
ES (2) ES2004952A6 (OSRAM)
FI (1) FI89052C (OSRAM)
FR (1) FR2601014B1 (OSRAM)
GB (1) GB2192183B (OSRAM)
GR (1) GR871014B (OSRAM)
HK (1) HK47893A (OSRAM)
HU (1) HU200777B (OSRAM)
IE (1) IE59613B1 (OSRAM)
IL (1) IL83059A (OSRAM)
IT (1) IT1211469B (OSRAM)
NL (1) NL193136C (OSRAM)
NO (1) NO170889C (OSRAM)
NZ (1) NZ220764A (OSRAM)
PL (1) PL159180B1 (OSRAM)
RU (1) RU1829932C (OSRAM)
SE (1) SE466257B (OSRAM)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
US5599557A (en) * 1992-04-30 1997-02-04 Schering Corporation Stable hydrated cephalosporin dry powder for oral suspension formulation
JP2002528575A (ja) * 1998-10-27 2002-09-03 イーストマン ケミカル カンパニー オレフィンの重合方法、新規ポリエチレン並びにそれから製造されるフィルム及び物品
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
AT412213B (de) * 2000-05-30 2004-11-25 Sandoz Ag Verfahren zur trocknung von amoxicillin oder amoxicillin-hältigen, oralen, festen pharmazeutischen zusammensetzungen unter verwendung eines gases mit einer definierten gasfeuchte
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
EP1648415A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2674831A1 (en) 2006-12-22 2008-11-13 Schering Corporation 5,6-ring annulated indole derivatives and methods of use thereof
MX2009006880A (es) 2006-12-22 2009-07-03 Schering Corp Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
JP5211068B2 (ja) * 2006-12-22 2013-06-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
CA2697500A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
EP2197842B1 (en) * 2007-08-29 2012-05-23 Schering Corporation 2, 3-substituted indole derivatives for treating viral infections
ES2447543T3 (es) * 2007-08-29 2014-03-12 Merck Sharp & Dohme Corp. Derivados de indol sustituidos y métodos de utilización de los mismos
CA2705586A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
EP2222672B1 (en) * 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
WO2009152200A1 (en) * 2008-06-13 2009-12-17 Schering Corporation Tricyclic indole derivatives and methods of use thereof
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
ES2439009T3 (es) 2008-08-20 2014-01-21 Merck Sharp & Dohme Corp. Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales
WO2010022126A1 (en) 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
PL2451445T3 (pl) 2009-07-06 2019-09-30 Boehringer Ingelheim International Gmbh Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
WO2011139253A2 (en) 2010-05-04 2011-11-10 Mahmut Bilgic Pharmaceutical compositions comprising ceftibuten
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2696681B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2013151518A1 (en) * 2012-04-04 2013-10-10 Mahmut Bilgic Capsule formulations comprising ceftibuten
EP2815743A1 (en) 2013-06-21 2014-12-24 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten formulations
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
CN103948932B (zh) * 2014-04-17 2016-03-16 海南日中天制药有限公司 一种头孢克肟组合物及其制备方法
EP3031450A1 (en) 2014-12-12 2016-06-15 Sanovel Ilac Sanayi ve Ticaret A.S. Ceftibuten capsule compositions
CA3022684A1 (en) 2016-05-13 2017-11-16 Aeromics, Inc. Crystals
MY196909A (en) 2016-06-30 2023-05-09 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
CN106397454B (zh) * 2016-08-30 2018-08-24 山东罗欣药业集团股份有限公司 一种抗感染药物头孢布烯晶型化合物及其组合物
CN106432270A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106397457A (zh) * 2016-09-21 2017-02-15 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
CN106432272A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种制备治疗外科手术感染的药物头孢布烯晶体化合物的方法
CN106432271A (zh) * 2016-09-21 2017-02-22 临沂草之美医药科技有限公司 一种治疗外科手术感染的药物头孢布烯晶体化合物
US12552815B2 (en) 2020-05-05 2026-02-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
US20240327426A1 (en) * 2021-07-01 2024-10-03 Qpex Biopharma, Inc. Crystalline forms of ceftibuten

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2154580A (en) * 1983-10-04 1985-09-11 Shionogi & Co Carboxyalkenamidocephalosporins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3819620A (en) * 1972-06-01 1974-06-25 Squibb & Sons Inc 7-(d-alpha-amino-1,4-cyclohexadien-1-ylacet-amido)desacetoxycephalosporanic acid dihydrate
JPS5726692A (en) * 1980-07-22 1982-02-12 Fujisawa Pharmaceut Co Ltd Preparation of stable crystal of salt of ceftizoxime
DE3037997A1 (de) * 1980-10-08 1982-05-13 Bayer Ag (beta) -lactamantibiotika, verfahren zu deren herstellung sowie sie enthaltende mittel
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
AU580855B2 (en) * 1985-03-29 1989-02-02 Shionogi & Co., Ltd. Alkeneamidocephalosporin esters

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2154580A (en) * 1983-10-04 1985-09-11 Shionogi & Co Carboxyalkenamidocephalosporins

Also Published As

Publication number Publication date
HK47893A (en) 1993-05-27
PL159180B1 (pl) 1992-11-30
KR950005302B1 (ko) 1995-05-23
GR871014B (en) 1987-11-02
FR2601014B1 (fr) 1990-09-14
KR880001670A (ko) 1988-04-26
IT1211469B (it) 1989-11-03
CH672788A5 (OSRAM) 1989-12-29
ES2004952A6 (es) 1989-02-16
GB8715064D0 (en) 1987-08-05
PL266567A1 (en) 1988-07-21
DK161080C (da) 1991-11-11
FI872903A0 (fi) 1987-07-01
AU7504087A (en) 1988-01-07
ES2008759A6 (es) 1989-08-01
FI89052C (fi) 1993-08-10
IL83059A0 (en) 1987-12-31
BE1001691A4 (fr) 1990-02-13
IE871738L (en) 1988-01-02
SE8702705L (sv) 1988-01-03
HU200777B (en) 1990-08-28
DE3721913A1 (de) 1988-01-07
NL8701507A (nl) 1988-02-01
IE59613B1 (en) 1994-03-09
ATA165887A (de) 1990-09-15
NZ220764A (en) 1989-09-27
AU594167B2 (en) 1990-03-01
NO872729L (no) 1988-01-04
DK336487D0 (da) 1987-06-30
RU1829932C (ru) 1993-07-23
CN1015106B (zh) 1991-12-18
CN87105009A (zh) 1988-03-23
CA1283405C (en) 1991-04-23
FI872903L (fi) 1988-01-03
HUT44257A (en) 1988-02-29
US4812561A (en) 1989-03-14
IT8767566A0 (it) 1987-07-01
FR2601014A1 (fr) 1988-01-08
IL83059A (en) 1992-03-29
NL193136C (nl) 1998-12-04
NO170889C (no) 1992-12-23
SE8702705D0 (sv) 1987-06-30
DK161080B (da) 1991-05-27
US4933443A (en) 1990-06-12
NL193136B (nl) 1998-08-03
FI89052B (fi) 1993-04-30
NO170889B (no) 1992-09-14
NO872729D0 (no) 1987-06-30
AR243893A1 (es) 1993-09-30
GB2192183A (en) 1988-01-06
DK336487A (da) 1988-01-03
AT392472B (de) 1991-04-10
SE466257B (sv) 1992-01-20

Similar Documents

Publication Publication Date Title
AR243893A1 (es) Un procedimiento para preparar un hidrato cristalino del acido 7 beta-((z)) 2-(2-aminotiazol-4-il)-4-carboxibut-2-enoilamino)-3-cefem-4-carboxil ico
EP0363748A3 (en) Oral compositions
GB8904454D0 (en) Oral compositions
PH25375A (en) Oral compositions
PH25851A (en) Oral compositions
HK91893A (en) Oral compositions
GB8811829D0 (en) Oral compositions
PH25757A (en) Oral compositions
GB2187384B (en) Oral compositions
IL87905A0 (en) Crystalline beta-lactam hydrate
EP0371542A3 (en) Oral composition
GB8801470D0 (en) Oral compositions
EP0311260A3 (en) Oral compositions
GB8826333D0 (en) Oral compositions
GB8713040D0 (en) Oral compositions
GB2213721B (en) Oral hygiene composition
ZA878835B (en) Cephalosporin derivatives and their crystalline derivatives
GB8723116D0 (en) Oral compositions
GB8724544D0 (en) Oral compositions
GB8723117D0 (en) Oral compositions
PH24474A (en) A crystalline hydrate of oral cephalosporin
PH25510A (en) A composition of crystalline cephalosporin hydrates
ZA873010B (en) Crystalline hydrate
GB8818012D0 (en) Oral compositions
IE883770L (en) Oral compositions

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20070625